Gilead Sciences (NASDAQ:GILD) Finalizes Acquisition of TREX1 Program from Sprint Bioscience

Highlights 

• Sprint Bioscience AB sells its TREX1 cancer program to Gilead Sciences  
• Deal includes an upfront payment of USD 14 million and milestones up to USD 400 million 
• Transaction aligns with Sprint Bioscience’s shift toward flexible, value-driven exit strategies 
• TREX1 program has shown encouraging pre-clinical potential 
• Agreement strengthens Gilead’s expanding oncology-focused research pipeline 

Gilead Sciences (NASDAQ:GILD) has completed the acquisition of the TREX1 cancer program from Sprint Bioscience AB. The agreement includes an upfront payment of USD 14 million and future potential milestone payments that could reach as high as USD 400 million. 

The TREX1 program, which has displayed meaningful potential during pre-clinical evaluations, targets key mechanisms linked to cancer progression and immune evasion. 

Sprint Bioscience chose a full sale instead of a traditional licensing arrangement, a move the company views as supporting greater flexibility and value optimization. This approach aligns with its long-term objective of building a portfolio that creates recurring exit opportunities with attractive financial returns.

TREX1 Program’s Scientific Promise

The TREX1 program is designed to inhibit the TREX1 enzyme, a regulator associated with DNA degradation and immune modulation within cancer cells. By disrupting this pathway, the therapy aims to enhance antitumor immune responses and potentially improve outcomes when paired with other oncology treatments. Early-stage data generated by Sprint Bioscience has demonstrated encouraging activity, strengthening the program’s appeal to larger pharmaceutical partners. 

Gilead Sciences’ acquisition signals its continued commitment to expanding its oncology pipeline withassetsthat can synergize with its established research platforms. The company has been pursuing novel mechanisms that could enhance the performance of immunotherapies and targeted treatments, making the TREX1 program a strategically aligned addition.

Commercial and Developmental Potential for Both Companies

The financial terms of the deal offer Sprint Bioscience both immediate liquidity and significant long-term upside. The milestone payments cover clinical development progress, regulatory approvals across regions, and commercial achievements, giving Sprint Bioscience multiple opportunities to benefit from the program’s advancement under Gilead’s stewardship. 

For Gilead Sciences, theacquisitionadds another innovative tool to their oncology development portfolio. With its global reach and established infrastructure, Gilead is well-positioned to accelerate the program into clinical testing and explore its potential in combination with existing therapeutics. 

Conclusion 

The sale of the TREX1 program marks an important milestone for Sprint Bioscience AB, further reinforcing its strategy of developing commercially attractive oncology assets and executing well-timed divestments. With TREX1 now in the hands of Gilead Sciences, the program stands to move more rapidly toward clinical evaluation, while Sprint Bioscience gains both financial resources and strategic momentum. This partnership highlights the continued interest from global pharmaceutical leaders in early-stage cancer innovations emerging from Sweden’s biotechnology sector. 

Gilead Sciences’ shares closed at USD 126.64, marking a 1.32% increase from the prior session. 

Also read -SynCardia Systems (NASDAQ:PMI) Reaches Milestone with First Implantations of Emperor Artificial Heart